ERBB2 and metastatic neoplasm: According to the aforementioned evidence, nowadays, it is recommended by several clinical guidelines that first recurrence disease should be re-biopsied to confirm pathology diagnosis and re-assess ER, PR and HER2 status on recurrent/metastatic tumor if possible (13–16).